Skip to main content

Table 5 Clinical parameters, antimicrobial regimens and treatment outcome of patients with bloodstream infection (BSI) due to ESBL-negative P. aeruginosa (ESBL-N-Pa) isolates

From: Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum beta-lactamase

Isolate Age (yr) Sex a McCabe & Jackson b Charlson weighted
index
Primary source(s)
of infection c
Severity of
septicemia
Empirical
treatment
Treatment administered after
ID and AST d results
Treatment
outcome e
        Agent
(daily dose)
Adequate Agent
(daily dose)
Timing from
BSI onset
Duration
(days)
 
299/98 40 M NF 0 LRTI, WI Septic shock IPM (1 g × 3) Yes Not changed Day 1 12 FA
77/99 76 M UF 4 LRTI, UTI Sepsis IPM (0.5 × 3) Yes Not changed Day 0 14 CR
251/00 55 M UF 6 Unknown Sepsis IPM (0.5 g × 2) Yes Not changed Day -1 1 NA
746/00 64 M NF 2 UTI Sepsis PIP (2 g × 2)
CIP (0.5 g)
No IPM (0.5 g × 2) Day 5 7 CR
2497/01 34 M NF 1 Unknown Sepsis PIP (2 g × 2) No CIP (0.5 g × 2) Day 5 3 CR
2544/01 79 F UF 3 Unknown Sepsis NET (0.15 g × 2) No IPM (0.5 g × 3) Day 1 13 CR
A372/02 67 M RF 7 WI Severe sepsis CIP (0.5 g × 2)
AMK (0.5 g × 2)
No IPM (0.5 × 2) Day 4 9 CR
A480/02 69 F NF 0 LRTI, WI Sepsis CIP (0.4 g × 2) Yes Not changed Day 1 10 FA
659/02 71 M RF 8 UTI Sepsis IPM (0.5 g × 2) Yes Not changed Day 0 8 CR
694/02 93 M UF 3 IVC Sepsis PTZ (2.25 g × 3) Yes PTZ (2.25 g × 3)
AMK (0.5 g × 2)
Day 0
Day 6
7 2 CR
A276/03f 76 M NF 3 Unknown Sepsis None No IPM (1 g × 3) Day 3 10 PR
A562/03f 76 M NF 3 Unknown Sepsis PTZ (2.25 g × 3) Yes Not changed Day 0 15 CR
A173/03f 76 M NF 3 Unknown Sepsis PTZ (2.25 g × 3) Yes Not changed Day -1 29 CR
A590/03 64 M RF 6 LRTI, WI Sepsis IPM (1 g × 3) AMK (0.75 g) Yes AMK (1 g) Day 2 8 RE
A424/04 36 M UF 3 Unknown Septic shock IPM (0.5 g × 4) No MEM (1 g × 2) Day 4 19 FA
  1. Abbreviations for antimicrobial agents: NET, netilmicin; PIP, piperacillin; TZP, piperacillin plus tazobactam; CRO, ceftriaxone; FEP, cefepime; IPM, imipenem; MEM, meropenem; CIP, ciprofloxacin; AMK, amikacin; GEN, gentamicin.
  2. a Sex: F, female; M, male.
  3. b McCabe & Jackson classification: NF, nonfatal; UF, ultimately-fatal; RF, rapidly-fatal.
  4. c Primary source(s) of infection: LRTI, lower respiratory tract infection; WI, wound infection; UTI, urinary tract infection; IVC, intravascular catheter colonization.
  5. d ID, identification; AST, antimicrobial susceptibility test.
  6. e Treatment outcome: CR, complete response; PR, partial response; FA, failure; RE, relapse; NA, not assessable.
  7. f These strains caused three different BSI in the same patient.